Submitted by Anonymous (not verified) on 22 January 2025 - 13:51
Human medicines European public assessment report (EPAR): Lytenava, bevacizumab, Date of authorisation: 27/05/2024, Revision: 2, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Lytenava, bevacizumab, Date of authorisation: 27/05/2024, Revision: 2, Status: Authorised